Date Range
Type of Content
Author
Category
Study
Waiting for New Medicines: How Does Canada Compare to the United States and Europe?
Manufacturers delay drug launches in Canada due to government red tape
| by:
Dr. Nigel Rawson
Study
Regulatory, Reimbursement, and Pricing Barriers to Accessing Drugs for Rare Disorders in Canada
Ottawa’s drug-pricing changes threaten Canadians who suffer from rare diseases
| by:
Dr. Nigel Rawson
Study
Has pCODR Improved Access to Oncology Drugs?
Approval of new cancer-fighting medicines delayed due to extra layer of bureaucratic review
| by:
Dr. Nigel Rawson
Study
Potential Impact of Delayed Access to Five Oncology Drugs in Canada
Potential Impact of Delayed Access to Five Oncology Drugs in Canada
| by:
Dr. Nigel Rawson
Study
Access to New Oncology Drugs in Canada Compared with the United States and Europe
Access to New Oncology Drugs in Canada Compared with the United States and Europe
| by:
Dr. Nigel Rawson
Commentary
Canadians wait much longer for drugs than Americans and Europeans
Appeared in the Appeared in National Newswatch
| by:
Dr. Nigel Rawson,
and Bacchus Barua
| by:
Dr. Nigel Rawson
| by:
Dr. Nigel Rawson
Commentary
Delayed drug approvals in Canada—here’s why
| by:
Dr. Nigel Rawson
| by:
Dr. Nigel Rawson